RxDoctor Payments Data

Dipen Shah, MD

Family Medicine · Cary, NCNPI 1750333993

Payments from drug & device makers

$6,004in general payments, 2019–2025

Across 310 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$641
  • Lilly USA, LLC$630
  • Astellas Pharma US Inc$604
  • GSK$560
  • Boehringer Ingelheim$301
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$5,80497%
  • Education$2003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,004 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$134,532
Medicare patients
240
Services billed
1,558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$82,930
JardianceEmpagliflozin39$53,146
EliquisApixaban41$36,036
ProliaDenosumab13$22,209
JanuviaSitagliptin Phosphate14$20,358
XareltoRivaroxaban11$13,331
SynjardyEmpagliflozin/Metformin Hcl15$9,607
Incruse ElliptaUmeclidinium Bromide14$7,062
Breo ElliptaFluticasone/Vilanterol14$5,705
SynthroidLevothyroxine Sodium36$3,242
Levothyroxine Sodium233$2,239
Colesevelam Hcl11$2,007
Rosuvastatin Calcium161$1,966
Omeprazole112$1,648
Atorvastatin Calcium203$1,609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,415$82,93073 claims
Boehringer IngelheimJardiance, Synjardy$301$62,75354 claims
PfizerEliquis$182$36,03641 claims
AmgenProlia$115$22,20913 claims
MerckJanuvia$132$20,35814 claims
Johnson & JohnsonXarelto$16$13,33111 claims
GSKIncruse Ellipta, Breo Ellipta$560$12,76728 claims
AbbVieSynthroid$641$3,24236 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$25$2,239233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Cary

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →